Table 1.
Baseline demographic, clinical and inflammatory parameters of patients with SARS-Cov-2 pneumonia in medical ward setting, according to the need of ICU admission.
| Variables | Ward setting-treated patients (n = 39) | p | |
|---|---|---|---|
| No ICU care n = 32 | ICU care n = 7 | ||
| Age, years [median(IQR)] | 64·5 (54·3–73·8) | 75·0 (71·0–79·0) | 0·01 |
| Male, n(%) | 30 (93·8) | 6 (85·7) | 0·47 |
| Weight, Kg [median(IQR)] | 80 (70·0–83·0) | 84 (75·0–100·0) | 0·21 |
| Overweight/obese, n(%) | 17 (53·1) | 6 (85·7) | 0·11 |
| SIGNS AND SYMPTOMS | |||
| Fever, n(%) | 39 (100·0) | 14 (100·0) | 1·00 |
| cough, n(%) | 20 (51·3) | 9 (64·3) | 0·40 |
| dyspnea, n(%) | 23 (59·0) | 8 (57·1) | 0·91 |
| Days from symptoms to SARI infusion, [median(IQR)] | 11 (9·0–15·0) | 8 (3·0–11·0) | 0·06 |
| FiO2 | 40 (35·0–50·0) | 60 (40·0–60·0) | 0·04 |
| PaO2/FiO2 | 167·5 (125·4–226·5) | 101·0 (89·0–141·0) | 0·007 |
| LABORATORY FINDINGS | |||
| White blood cells count, x103/ml [median(IQR)] | 6·1 (4·7–6·8) | 7·1 (5·7–10·1) | 0·22 |
| Lymphocytes count, x103/ml [median(IQR)] | 0·8 (0·6–0·9) | 0·7 (0·5–0·9) | 0·38 |
| neutrophils/lymphocytes ratio, [median(iqr)] | 5·7 (4·2–11·3) | 8·0 (6·3–12·5) | 0·22 |
| hemoglobin, g/l [median(iqr)] | 13·0 (11·8–13·9) | 13·3 (12·3–13·5) | 0·91 |
| Platelet, x103/ml [median(IQR)] | 304 (247–420) | 271 (246·3–303·8) | 0·30 |
| Albumin, g/L [median(IQR)] | 2·9 (2·7–3·1) | 3·1 (2·7 −3·8) | 0·28 |
| D-dimers, mg/L [median(IQR)] | 1345 (1056·5–2702) | 1955 (1108·3–3828·5) | 0·64 |
| GPT, mg/L [median(IQR)] | 32·5 (22·5–48·0) | 34·0 (17·0–48·0) | 0·82 |
| Creatinine, mg/L [median(IQR)] | 0·9 (0·7–1·2) | 1·2 (0·7–1·5) | 0·33 |
| C-Reactive Protein, mg/L [median(IQR)] | 148·5 (59·2–200·1) | 132·0 (102·8–161·5) | 0·78 |
| Lactate Dehydrogenase, [median(IQR)] | 315 (245·5–398·3) | 350 (306·5–469·0) | 0·24 |
| SOLUBLE BIOMARKERS | |||
| IL-6 plasma levels, pg/ml [median(IQR)] | 63·9 (30·0–103·7)*24 | 116·3 (86·3–203·7)*6 | 0·05 |
| COMORBIDITY | |||
| Diabetes, n(%) | 6 (18·8) | 1 (14·3) | 0·78 |
| Hypertension, n(%) | 15 (46·9) | 6 (85·7) | 0·06 |
| Cardiovascular disease, n(%) | 5/28 (17·9) | 2/6 (33·3) | 0·40 |
| Chronic Obstructive pulmonary disease, n(%) | 3/28 (10·7) | 1/6 (16·7) | 0·55 |
| Malignancy, n(%) | 0/28 (0·0) | 0/6 (0·0) | 1·00 |
| Dyslipidemia, n(%) | 6/29 (20·7) | 2/6 (33·3) | 0·50 |
| Chronic Infection, n(%) | 3/28 (10·7) | 0/6 (0·0) | 0·40 |
ICU: Intensive Care Unit; IQR: interquartile range; SARI: sarilumab; FiO2: fractional inspired oxygen; PaO2: arterial oxygen partial pressure; GPT: glutamine-pyruvate transaminase; IL: interleukin; g/L: grams/liter. *number of patients with available IL-6 value.